Resources from the same session
121MO - Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: final analysis from the randomized part 2 of the phase 1/2 CA027-002 study
Presenter: Matteo Simonelli
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
176MO - ORCA-010 Oncolytic Therapy: Inducing Tumor-Specific Immune Responses and Activation of Tumor Microenvironment in Treatment-Naïve Prostate Cancer
Presenter: Tanja de Gruijl
Session: Mini Oral session 2
Resources:
Abstract